2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120519
    L-665871 123788-05-6 98%
    L-665871 is a orally active β-adrenergic receptor agonist that can be used as a swine growth promoter.
    L-665871
  • HY-120542
    SR 1824 1338259-06-5 98%
    SR 1824 is a non-agonist PPARγ ligand that blocks Cdk5-mediated phosphorylation. SR 1824 has anti-diabetic effects.
    SR 1824
  • HY-120556
    tetranor-12(R)-HETE 135271-51-1 98%
    tetranor-12(R)-HETE is a metabolite of 12(R)-HETE formed via β-oxidation.
    tetranor-12(R)-HETE
  • HY-120598
    ASP7657 free base 1196045-28-9 99.30%
    ASP7657 free base is an orally active EP4 receptor antagonist, with Kis of 2.21 and 6.02 nM for the human and rat EP4 receptors.
    ASP7657 free base
  • HY-120608
    BMS-814580 1197420-11-3 98%
    BMS-814580 is an orally active, highly efficacious MCHR1 inhibitor with a Ki of 16.9 nM against hMCHR1. BMS-814580 shows antiobesity activities.
    BMS-814580
  • HY-120643
    BMS-823778 hydrochloride 1140898-87-8 98%
    BMS-823778 hydrochloride is a potent, selective and orally active 11β-HSD1 inhibitor with an IC50 of 2.3 nM against human 11β-HSD1.
    BMS-823778 hydrochloride
  • HY-12066A
    GSK-1292263 hydrochloride 1032824-54-6 98%
    GSK-1292263 (hydrochloride) is an orally active GPR119 agonist (pEC50 of approximately 6.9 and 6.7 nM for human and rat GPR119, respectively). GSK-1292263 is used in the research of type 2 diabetes and dyslipidemia.
    GSK-1292263 hydrochloride
  • HY-120711
    BRD0476 1314958-91-2 98%
    BRD0476 is an inhibitor of pancreatic β-cell apoptosis with an EC50 value of 0.78 μM and a maximal inhibitory activity of 99%. BRD0476 can be used in diabetes-related research.
    BRD0476
  • HY-120743
    Triplin 1421584-86-2 98%
    Triplin is a copper chelator, Triplin perturbs copper ion transport involved in the interaction of RAN1 and ATX1. Triplin suppresses the toxic effects of excess copper ions on plant root growth. Triplin increases the RNA expression of ERF1. Triplin acts through the ethylene signal transduction pathway. Triplin also is a bacterial pore-former.
    Triplin
  • HY-120800
    KUNG29 1887032-92-9 98%
    KUNG29 is a potent and selective Grp94 inhibitor with a Kd of 0.2 μM. KUNG29 induces the degradation of integrin α2 in MDA-MB-231 cells.
    KUNG29
  • HY-120847
    BI 186908 1453500-36-1 98%
    BI 186908 is a selective and orally active MCH receptor 1 antagonist with an IC50 of 22 nM and a Ki of 14 nM. BI 186908 binds with comparably high affinity to the recombinant human, cynomolgus monkey (IC50 of 18 nM), dog (IC50 of 23 nM) and rat (IC50 of 18 nM) MCH-R1. BI 186908 can significantly reduce the body weight of diet-induced obese rats. BI 186908 can be used for the study of obesity.
    BI 186908
  • HY-120943
    K-111 221564-97-2 98%
    K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome.
    K-111
  • HY-120969
    Docosanoyl ethanolamide 94109-05-4 99.9%
    Docosanoyl Ethanolamide (N-(2-hydroxyethyl)-docosanamide) is an ester product.
    Docosanoyl ethanolamide
  • HY-120971
    N-Decanoyl p-Nitroaniline 72298-63-6 99.9%
    N-Decanoyl p-nitroaniline (DepNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DepNA to FAAH activity results in the release of the yellow colorimetric dye p-nitroaniline (ε=13,500 at 410 nm). This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
    N-Decanoyl p-Nitroaniline
  • HY-120989
    Methyl 7(Z)-hexadecenoate 56875-67-3 98%
    Methyl 7(Z)-hexadecenoate is a sex pheromone produced by Trogoderma glabrum. Methyl 7(Z)-hexadecenoate can elicit attractive and sexually excitatory responses in Trogoderma glabrum males.
    Methyl 7(Z)-hexadecenoate
  • HY-121029
    Bisegliptin 862501-61-9 98%
    Bisegliptin (KRP-104) is a small molecule compound with antidiabetic activity. Bisegliptin is metabolized mainly by converting the cyano group to the carboxylic acid form, and DPP-4 plays a partial role in its metabolism. The carboxylic acid metabolite of bisegliptin can be detected both in vivo and in vitro. In rat experiments, the plasma concentration of the carboxylic acid metabolite of bisegliptin was affected by other DPP inhibitors, showing the complexity of its metabolic process. The amide intermediate of bisegliptin was detected both in vivo and in vitro, and its conversion rate was significantly faster than that of the parent compound when incubated with DPP-4.
    Bisegliptin
  • HY-121057
    3-Hydroxyflunitrazepam 67739-71-3 98%
    3-Hydroxyflunitrazepam (3-OH FNTZ) is the major metabolite of Flunitrazepam (FNTZ), generated via 3-hydroxylation by CYP3A4 (Km = 286 μM), and represents the dominant metabolic pathway (>80%) in liver microsomes. Its formation is significantly inhibited by CYP3A4 inhibitors such as Ketoconazole (HY-B0105) (IC50 = 0.11 μM) and Ritonavir (HY-90001) (IC50 = 0.041 μM), indicating a strong dependence on CYP3A4 activity and potential drug interactions.
    3-Hydroxyflunitrazepam
  • HY-121058
    AD 4743 87858-57-9 98%
    AD 4743 (ADD 4743) is a metabolite of Ciglitazone (HY-W011220). AD 4743 is an adipogenic agent. AD 4743 induces FPRP accumulation and accumulation of lipid droplets. AD 4743 inhibits cell proliferation of preadipose cells.
    AD 4743
  • HY-121070
    AZD1092 871656-65-4 98%
    AZD1092 is an orally active glucokinase (GK) activator with an EC50 value of 0.03 μM. AZD1092 can be used for the research of Type 2 Diabetes (T2D).
    AZD1092
  • HY-121110
    Fexarene 574013-68-6 98%
    Fexarene is a potent and selective nonsteroidal Farnesoid X Receptor (FXR) agonist with an EC50 of 36 nM. Fexarene can be used in studies of cholesterol and bile acid metabolism.
    Fexarene
Cat. No. Product Name / Synonyms Application Reactivity